Clinical Trial Update: Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the REPLY MR-conditional Pacing System for dual-chamber pacemaker placement has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrioventricular Block
• Bradycardia
• Cardiac Conduction Disease

Drugs mentioned

• REPLY MR-conditional Pacing System

Snippet

Sponsor: LivaNova | Conditions: Dual-chamber Pacemaker Placement | Phase 3 | Status: WITHDRAWN